Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
151-165 of 4127 results
EyeGate’s ocular bandage gel demonstrates positive effect in pilot trial
By PBR Staff Writer
The first-in-human pilot study evaluating EyeGate Pharmaceuticals’ EyeGate Ocular Bandage Gel (OBG) has yielded positive results.
Contract Research & Services > Clinical Trials > News
Kainos Medicine starts phase 1 trials of Parkinson's Disease drug candidate
Kainos Medicine has started phase 1 clinical trials of its Parkinson's Disease drug candidate code-named KM-819.
Contract Research & Services > Clinical Trials > News
Aurinia selects Worldwide Clinical Trials as CRO for phase 3 lupus nephritis study
Worldwide Clinical Trials has been selected as Aurinia Pharmaceuticals' clinical research organization (CRO) for the AURORA phase 3 study of volcosporin to treat active lupus nephritis (LN).
Contract Research & Services > Clinical Trials > News
Pfizer unveils positive results from phase 2 study of Clostridium difficile vaccine
By PBR Staff Writer
A phase 2 study evaluating Pfizer's investigational vaccine candidate for the prevention of Clostridium difficile (C. difficile) has yielded positive results.
Contract Research & Services > Clinical Trials > News
Eisai's liver cancer drug Lenvima succeeds in phase 3 trial
Eisai has announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib (marketed as Lenvima), for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Contract Research & Services > Clinical Trials > News
Onxeo completes enrollment in phase 3 hepatocellular carcinoma treatment trial
By PBR Staff Writer
Danish pharma company Onxeo has completed enrollment of patients in the phase 3 clinical trial of its advanced hepatocellular carcinoma (HCC) drug Livatag (doxorubicin transdrug).
Contract Research & Services > Clinical Trials > News
Actelion’s PAH drug fails to meet primary objective in Phase III study
By PBR Staff Writer
A Phase III study evaluating Actelion's macitentan in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger Syndrome failed to meet its primary goal.
Contract Research & Services > Clinical Trials > News
FDA authorizes NantKwest’s IND application for first-in-human haNK cell therapy phase I study
The US Food and Drug Administration (FDA) has authorized NantKwest’s Investigational New Drug Application (IND) for its first-in-human, high-affinity natural killer (haNK) cell therapy phase I clinical study.
Contract Research & Services > Clinical Trials > News
OncoMed doses first patient in phase 1b trial of brontictuzumab
OncoMed Pharmaceuticals has dosed the first patient in a Phase 1b clinical trial of brontictuzumab (anti-Notch1, OMP-52M51) plus chemotherapy in metastatic colorectal cancer patients.
Contract Research & Services > Clinical Trials > News
Otonomy starts patient enrollment in phase 2 trial of OTO-104
Otonomy has started the enrollment of the first patients in a phase 2 clinical trial assessing OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.
Contract Research & Services > Clinical Trials > News
Clinigen begins US Managed Access program for TESARO’s niraparib in ovarian cancer patients
Clinigen Group's Idis Managed Access (MA) division has partnered with TESARO to launch a Managed Access program for the investigational PARP 1/2 inhibitor, niraparib.
Contract Research & Services > Clinical Trials > News
Evgen Pharma doses first patient in phase II breast cancer trial
Evgen Pharma has dosed the first patient in its Phase II clinical trial of SFX-01 in breast cancer.
Contract Research & Services > Clinical Trials > News
AstraZeneca refines endpoints in immuno-oncology trials for NSCLC
By PBR Staff Writer
AstraZeneca has refined the endpoints of its phase III clinical trial, Mystic, evaluating durvalumab and tremelimumab for first-line treatment of patients with non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Chi-Med starts phase II study of sulfatinib in second-line biliary tract cancer in China
Hutchison China MediTech (Chi-Med) has started a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China.
Contract Research & Services > Clinical Trials > News
ObsEva completes phase 1 first-in-women study of OBE022 to treat preterm labor
ObsEva has completed a Phase 1 single and multiple ascending dose study of OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2α, or PGF2α, receptor antagonist for the treatment of preterm labor in weeks 24 to 34 of pregnancy.
Contract Research & Services > Clinical Trials > News
151-165 of 4127 results